Development of a light-initiated chemiluminescent assay platform for rapid detection of multiple inflammatory biomarkers.

Journal: Talanta
Published Date:

Abstract

The accurate and timely detection of inflammatory biomarkers, including C-reactive protein (CRP), interferon-γ (IFN-γ), and procalcitonin (PCT), is critical for the diagnosis and monitoring of various diseases. Traditional immunoassays often suffer from complex workflows, long incubation times, and limited multiplexing capabilities, which restrict their utility in high-throughput or point-of-care applications. To overcome these challenges, we developed a light-initiated chemiluminescent assay (LICA) platform, leveraging the synthesis and functionalization of photosensitive microspheres and luminescent microspheres encapsulated with β-diketonate-Eu(III) complexes for the rapid detection of CRP, IFN-γ, and PCT. The LICA platform exhibited excellent analytical performances, achieving detection limits of 6.2 ng mL for CRP, 0.32 pg mL for IFN-γ, and 0.012 ng mL for PCT, alongside remarkable specificity and reproducibility. We further validated the LICA platform by analyzing clinical blood samples, and the results were in excellent agreement with those obtained using well-established clinical methods, with a correlation coefficient exceeding 0.9940. Mechanistic investigations revealed that singlet oxygen is the key reactive species driving luminescence, while efficient intramolecular energy transfer from the ligands to the Eu(III) metal center plays a critical role in the emission of luminescence. Our findings underscore the potential of the LICA platform as a transformative tool for the detection of multiple inflammatory biomarkers, particularly in scenarios requiring rapid, multiplexed detection of inflammatory biomarkers.

Authors

  • Jinlian Huang
    Guangdong Provincial Engineering Technology Research Center of Public Health Detection and Assessment, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, 510310, PR China.
  • Mengtian Xiong
    Guangdong Provincial Engineering Technology Research Center of Public Health Detection and Assessment, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, 510310, PR China.
  • Xiaoqi Ou
    Guangdong Provincial Engineering Technology Research Center of Public Health Detection and Assessment, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, 510310, PR China.
  • Haiqin Li
    Guangdong Provincial Engineering Technology Research Center of Public Health Detection and Assessment, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, 510310, PR China.
  • Shibo Shang
    Department of Laboratory Medicine, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, 510317, PR China.
  • Zhiming Huo
    Guangdong Provincial Engineering Technology Research Center of Public Health Detection and Assessment, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, 510310, PR China.
  • Liangshan Hu
    Department of Laboratory Medicine, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, 510317, PR China. Electronic address: liangshan8027@163.com.
  • Qingsong Chen
    Guangdong Provincial Engineering Technology Research Center of Public Health Detection and Assessment, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, 510310, PR China. Electronic address: qingsongchen@aliyun.com.
  • Runkun Zhang
    Guangdong Provincial Engineering Technology Research Center of Public Health Detection and Assessment, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, 510310, PR China. Electronic address: zhangrk@gdpu.edu.cn.

Keywords

No keywords available for this article.